Xtant Medical Holdings Inc与Dilon Technologies共同宣布，双方已签署一项具有排他性的经销协议。根据协议条款，Xtant Medical将获得Dilon旗下创新产品Hemoblast® Bellows在美国市场的独家分销权。这一合作标志着两家企业在医疗器械领域战略布局的重要延伸，旨在通过资源整合提升产品市场渗透力。Hemoblast® Bellows作为先进的医疗解决方案，其独家经销权的落地预计将为双方带来新的增长动能。
Xtant Medical Holdings Inc与Dilon Technologies共同宣布，双方已签署一项具有排他性的经销协议。根据协议条款，Xtant Medical将获得Dilon旗下创新产品Hemoblast® Bellows在美国市场的独家分销权。这一合作标志着两家企业在医疗器械领域战略布局的重要延伸，旨在通过资源整合提升产品市场渗透力。Hemoblast® Bellows作为先进的医疗解决方案，其独家经销权的落地预计将为双方带来新的增长动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.